Alzheimer's disease (AD) is a neurodegenerative brain disorder that has an increasingly
large burden on health and social care systems. The pathophysiology involves the …

Currently, the field is awaiting the results of several pivotal Phase III clinical Alzheimer's
disease (AD) trials that target amyloid-β (Aβ). In light of the recent biomarker studies that …

ABSTRACT Introduction Alzheimer's Disease (AD) represents a large and growing
challenge to patients, carers and healthcare systems, yet extensive efforts to develop …

Worldwide multidisciplinary translational research has led to a growing knowledge of the
genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that …

Alzheimer's disease (AD) is the most common form of dementia, with prevalence and the
accompanying socioeconomic impact set to increase over the coming decades. Currently …

Alzheimer's disease (AD) is one of the most common multifactorial diseases, including a
range of abnormal cellular/molecular processes occurring in different regions of the brain …

Alzheimer's disease is an age-related progressive neurodegenerative disorder with an
enormous unmet medical need. It is the most common form of dementia affecting∼ 5% of …

Alzheimer's disease (AD) is a neurodegenerative disorder that impairs mainly the memory
and cognitive function in elderly. Extracellular beta amyloid deposition and intracellular tau …

To date, Alzheimer disease (AD) drug candidates have produced negative results in human
trials, and progress in moving new targets out of the laboratory and into trials has been slow …

Alzheimer's disease (AD) has been a global concern for years due to its severe implications
that affects the quality of life of the patients. The available line of therapy for treating …